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Lipid biology continues to emerge as an area of sig-
nificant therapeutic interest, particularly as the result
of an enhanced understanding of the wealth of
signaling molecules with diverse physiological
properties. This growth in knowledge is epitomized
by lysophosphatidic acid (LPA), which functions
through interactions with at least six cognate G pro-
tein-coupled receptors. Herein, we present three
crystal structures of LPA1 in complex with antagonist
tool compounds selected and designed through
structural and stability analyses. Structural analysis
combinedwithmolecular dynamics identified a basis
for ligand access to the LPA1 binding pocket from the
extracellular space contrasting with the proposed
access for the sphingosine 1-phosphate receptor.
Characteristics of the LPA1 binding pocket raise
the possibility of promiscuous ligand recognition of
phosphorylated endocannabinoids. Cell-based as-
says confirmed this hypothesis, linking the distinct
receptor systems through metabolically related li-
gands with potential functional and therapeutic im-
plications for treatment of disease.
INTRODUCTION
Lysophosphatidic acid (LPA) is a pleiotropic bioactive lipid pro-
duced from extracellular lysophospholipids by autotaxin (ATX),
as well as derived from membrane glycerophospholipids by
phospholipases (Aoki, 2004; Hishikawa et al., 2014; Perrakis
and Moolenaar, 2014), to produce a range of chemical specieswith varied fatty acid chain length and saturation. LPA is present
in nearly all cells, tissues, and fluids of the body (Mirendil et al.,
2013) and its effects aremediated by cognate cell-surfaceGpro-
tein-coupled receptors (GPCRs) consisting of six family mem-
bers designated LPA1-LPA6 (Kihara et al., 2014) that couple to
heterotrimeric G protein complexes to activate downstream
signaling pathways. Targeted deletion of the LPA receptors
has revealed physiological effects on every organ system exam-
ined thus far, with receptor dysregulation linked to a range of dis-
ease indications including hydrocephalus (Yung et al., 2011),
infertility (Ye et al., 2005), fibrosis (Tager et al., 2008), pain (Inoue
et al., 2004), and cancer (Mills andMoolenaar, 2003). Three of the
six LPA receptors, including LPA1 (Kihara et al., 2014), are part of
a larger lysophospholipid receptor family (the EDG family) that in-
cludes the sphingosine 1-phosphate (S1P) receptors, of which
the structure of one member (S1P1) has been reported (Hanson
et al., 2012). The closely related cannabinoid receptor CB1
(Hecht et al., 1996; Matsuda et al., 1990) interacts with endoge-
nous ligands structurally related to LPA raising the question of
potential polypharmacology between the two receptors, effec-
tively connecting these signaling systems. Additional structural
details for this family will improve our understanding of their
associated function and physiology.
RESULTS
Design of LPA1 Ligands for Structural Studies
A key for success in GPCR structure determination is the identi-
fication of a ligand that stabilizes the receptor into a single and
stable conformation. To facilitate finding such a ligand, a stability
assay based on analytical size exclusion chromatography
(aSEC) was developed and used to screen a library of com-
pounds (Figure S1). The compound used for initial studies of
LPA1, ONO-9780307 (Table S1, Figure S5A and SupplementalCell 161, 1633–1643, June 18, 2015 ª2015 Elsevier Inc. 1633
Figure 1. The Overall Structure of LPA1
Colored by Region and Compound Struc-
ture in the Bioactive Conformation
(A) The ligand ONO-9780307, shown with green
carbons, demarcates the binding pocket, which is
partially occluded by an N-terminal alpha helix
(red) packing closely against the extracellular
loops, ECL1 and ECL2 (orange). There are three
native disulfide bonds in the extracellular region,
one of which constrains the N-terminal capping
helix to ECL2.
(B) The bioactive conformation of ONO-9780307 in
green carbons with high torsional strain energy
required for positioning the indane ring adjacent to
the dimethoxy phenyl ring. Release of this strain
with an optimal torsion angle would result in a
clash with the binding pocket.
Figure 2. Generation of the Disulfide Engineered LPA1 (dsLPA1-
mbRIL) Crystallization Construct
(A) Prediction of cysteine mutants replacing Asp2045.37 and Val2826.59 at the
tip of TMV and VI, respectively.
(B) Functional analysis of dsLPA1 and full-length wild-type LPA1 through a
calcium mobilization assay measured in response to LPA. The EC50 value of
the stabilized receptor (994 nM) is about 6-fold higher compared to wild-type
(153 nM). Data are presented as a mean (±SEM, n = 3).
(C) Thermal stability analysis of dsLPA1-bRIL compared to the non-engineered
crystallization construct LPA1-bRIL. The engineered disulfide bond increases
the apparent Tm by about 5
C in the presence of ONO-9780307, whichwas the
ligand used for stability characterization of new constructs.
(D) Crystal images for dsLPA1-mbRIL in the presence of ONO-3080573. See
also Figure S1.Experimental Procedures), was selected from this library based
on the initial SEC stability assay data (Figure S1) (Tanaka et al.,
2011). This assay was used in place of the more traditional
CPM assay (Alexandrov et al., 2008) to allow early access to sta-
bility data without the need for pure receptor protein. Using in-
sights gained from the initial structure, several analogs of
ONO-9780307 were designed by considering lipophilicity, struc-
tural diversity, and potential metabolic stability. These analogs
were synthesized (Supplemental Experimental Procedures),
tested for stability induction, and used to generate additional
co-crystal structures (Table S1). The design feature of ONO-
9910539 (Figure S5B) is an acetyl group for enhanced polar inter-
actions and reduced lipophilicity. The design of ONO-3080573
(Figure S3B) replaced a methylene and the pyrrole ring with an
ether and phenyl ring, respectively, to both reduce torsional
strain and increase structural diversity and potential metabolic
stability.
Structure Determination of LPA1-ONO-9780307,
LPA1-ONO-9910539, and LPA1-ONO-3080573
To facilitate crystallization, a thermostabilized b562RIL (bRIL)
(Chun et al., 2012), was inserted into the third intracellular loop
(3IL) at Ballesteros index positions 5.66 (R233) and 6.24 (R247)
(Ballesteros and Weinstein, 1995), and thirty-eight residues
were truncated from the carboxyl terminus (C terminus). With
this engineered construct (LPA1-bRIL) in complex with com-
pounds ONO-9780307 and ONO-9910539, crystals were pro-
duced in LCP supplemented with cholesterol that diffracted to
a final resolution of 3.0 A˚ and 2.9 A˚, respectively, and supported
structure solution (Figure 1A). Despite similar stability induction
for ONO-3080573 (Figure S1), we were unable to crystallize
this compound with the original LPA1-bRIL construct. In order
to further improve stability and reduce conformational heteroge-
neity for crystallization in the presence of ONO-3080573, a series
of disulfide bonds were engineered into various sites within the
extracellular half of the transmembrane region of LPA1-bRIL,
and onewas selected based on superior expression and stability
analysis (dsLPA1-bRIL) (Figures 2A and C). The effect of disulfide
bond engineering at this site was evaluated using signaling in1634 Cell 161, 1633–1643, June 18, 2015 ª2015 Elsevier Inc.response to LPA concentration in a calcium mobilization assay
(Figure 2B). To reduce conformational heterogeneity, bRIL was
modified by replacing a disordered loop with a short linker
(mbRIL). Crystals of dsLPA1-mbRIL in complex with ONO-
3080573 were grown in a LCP cholesterol mixture and diffracted
Figure 3. Comparison of S1P1 and LPA1
Structural Features
(A). Top-view of LPA1 with structurally divergent
regions of S1P1 (PDB ID: 3V2Y) overlayed (cyan).
The configuration of the extracellular region is
constrained by two intraloop disulfide bonds in
ECL2 and ECL3 and a disulfide bond connecting
ECL2 with the N terminus. Although the electron
density for the ECL3 loop is poor compared to the
rest of the structure, the approximate position
could be properly determined and is further from
the N-terminal helix compared to S1P1. In S1P1
Lys285 in this region forms a cation dipole inter-
action with the C-terminal end of the capping helix,
an interaction that ismissing in LPA1. TMI is shifted
3 A˚ closer to TMVII at the tip compared to S1P1
and ECL0 is a loop in LPA1. Neither ECL0 nor ECL3
are involved in crystal contacts.
(B). The shape of the LPA1 binding pocket is
spherical in nature (solid surface) compared to the
more linear binding pocket of S1P1 (bluemesh surface). This difference is caused by three changes in the amino acid composition between the two receptors. The
first at position 3.33 is an aspartate in LPA1 and a phenylalanine in S1P1. The second at position 5.43 is a tryptophan in LPA1 and a cysteine in S1P1. Finally at
position 6.51 LPA1 has a glycine, whereas S1P1 has a leucine. The reduction in side chain bulk at this position opens a sub-pocket occupied by the indane ring of
the antagonist series.to 2.9A˚ (Figure 2D). While there are clear differences in experi-
mental electron density for the ligands (Figure S2), aside from
small conformational changes in and around the binding pocket,
the receptor structures are highly analogous.
Overall Structural Features of LPA1 in Complex with
ONO-9780307
The initial co-crystal structure of LPA1-bRIL in the antagonist
state with the compound ONO-9780307 is used for a general
description of the receptor. The main fold of the antagonist
bound LPA1 receptor is similar to other inactive class A GPCRs,
with a canonical seven-transmembrane a-helical bundle (Fig-
ure 1A). The N terminus of LPA1 forms a six-turn alpha helix
similar in length and orientation to the equivalent residues in
S1P1, but with an additional disulfide bond linking the N-terminal
capping helix to extracellular loop 2 (ECL2), resulting in addi-
tional fold stability. The N terminus packs tightly against ECL1
and ECL2 and provides charged and polar amino acid side
chains for interactions within the ligand-binding pocket. The
ligand, ONO-9780307, positions its branching aromatic indane
and dimethoxy phenyl rings adjacent to each other in the spher-
ical binding pocket. This positioning requires a strained eclipsed
conformation of the torsion angle on the bond adjacent to the
indane ring, with a difference of 9.6 kcal/mol between the
observed conformation and the local energyminimum estimated
by gas-phase quantum mechanics calculations. The ligand
conformation associated with the local energy minimum is not
able to bind in the pocket due to projected clashes with TMVI
(Figure 1B).
Structural Comparison of the LPA1 and S1P1 Receptors
The relative orientation of LPA1 helices is similar to the S1P1
receptor, which was expected given the similarity in both
primary sequence (41% identical in the transmembrane region)
and recognition of lysophospholipid endogenous ligands (Chun
et al., 2013). The primary point of divergence occurs at the tipof TMI, which is positioned 3 A˚ closer to TMVII compared to
S1P1 (Figure 3A). This helical repositioning closes a gap between
TMI and TMVII, which was postulated to enable access of hydro-
phobic ligands to the occluded extracellular binding pocket via
the membrane for S1P1. The short segment between TMI and
the N-terminal capping helix (ECL0) is helical in S1P1 but lacks
secondary structure in LPA1. This change may open access to
the ligand binding pocket from the extracellular space through
increased flexibility and may also contribute to the inward shift
of TMI through a release of secondary structure steric con-
straints. Interestingly, ECL1 and ECL2 are comparable between
the two receptors, whereas the position of the third extracellular
loop (ECL3) diverges from the S1P1 receptor by up to 8 A˚ at the
furthest point, resulting in a loss of interactions between this loop
and the rest of the extracellular region (Figure 3A). The overall
result is the opening of a ligand access port into the extracellular
milieu for LPA1, while access from the plasma membrane is
closed (Figure 3A).
These global changes combined with residue substitutions
generate a binding pocket for LPA1 that is more spherical
compared to S1P1 (Figure 3B). This characteristic supports the
finding that LPA1 has the ability to recognize a more diverse
repertoire of chemical species of endogenous ligands with acyl
chains of different lengths and globular conformations beyond
the commonly used LPA 18:1 sn1. Three sequence substitutions
can be identified that alter both the shape and polarity of the LPA
receptor binding pocket compared to S1P receptors. In LPA re-
ceptors, position 3.33 is occupied by an aspartate residue
(Asp1293.33 in LPA1), whereas S1P receptors have a conserved
phenylalanine that serves an important role in ligand recognition
(van Loenen et al., 2011). At position 5.43, LPA receptors
possess a tryptophan residue (Trp2105.43 in LPA1), contrasting
with a cysteine residue at this position in most S1P receptors.
Finally, LPA receptors have a glycine (Gly2746.51 in LPA1) at po-
sition 6.51, contrastingwith a leucine or alanine that forms impor-
tant van der Waals interactions with the S1P ligands (Figure 3B).Cell 161, 1633–1643, June 18, 2015 ª2015 Elsevier Inc. 1635
Figure 4. Analysis of the Potential Ligand Entry for S1P1 and LPA1
(A) The position of TMI in S1P1 is shifted away from TMVII with a distance of
11 A˚ as measured between the Ca of Thr481.35 and Glu2947.36, this helical
position allows access of ligand (ML056 shown in green carbon sticks) in the
plasma membrane to the binding pocket of S1P1.
(B) The position of TMI in LPA1 is closer to TMVII closing access of ligand
(ONO-9780307 shown in green carbon sticks) in the plasma membrane to the
binding pocket. The closer packing of TMI relative to S1P1 may be driven by
the presence of Glu3017.43, which forms a hydrogen bond interaction with the
backbone of Gly561.39 and Val591.42.
(C) Molecular dynamics analysis of the distance between TMI and TMVII
measured at four locations represented by a box plot for each measurement
with the minimum and maximum indicated by vertical lines. The measure-
ments correspond to the distances shown in A˚ monitored over the course of
the simulation. The distance between the two helices is consistently larger and
more variable for S1P1 than LPA1 both with and without ML056 and ONO-
9780307 ligands, respectively.
1636 Cell 161, 1633–1643, June 18, 2015 ª2015 Elsevier Inc.Molecular Dynamics Analysis Supports Ligand Access
from Extracellular Space
The divergent position of TMI in LPA1 compared to S1P1 is attrib-
utable to both enhanced polar interactions and a substantial
reduction in volume at the interface of TMI and TMVII (Figures
4A and 4B). In order to further understand the mode of ligand ac-
cess for both LPA1 and S1P1, comparative molecular dynamics
simulations of both receptors were completed, with and without
their respective ligands, and the distance between the TMI and
TMVII heliceswas analyzed over the course of three independent
100 ns simulations for each receptor system. Based on this anal-
ysis, it is clear that the distance between TMI and TMVII in LPA1
is indeed smaller and less variable compared to that observed
for S1P1. The distances diverge most noticeably at the extracel-
lular tip of the helices, with a difference of approximately 7 A˚
between LPA1 and S1P1 in the absence of ligand (Figure 4C).
Overall, these results strengthen the conclusion that sequence
differences between TMI and TMVII on LPA1 and S1P1 result in
an altered ligand access path, whereby LPA1 preferentially re-
ceives ligands from the extracellular milieu compared to mem-
brane access for S1P1 ligands.
LPA1 Ligand Binding Interactions with ONO-9780307,
ONO-9910539, and ONO-3080573
Despite similar endogenous ligands, similar overall structural
characteristics, and mutagenesis studies suggesting simple
interchangeability between LPA1 and S1P1 (Wang et al., 2001),
structural comparisons of the pocket shape and polarity re-
vealed substantial divergence between the two receptors. At
the top of polar region of the binding pocket, the carboxylic
acid of ONO-9780307 interacts through polar and ionic bonds
with residues His40, Lys39, and Tyr34, all of which are located
on the N-terminal capping helix and ECL0 loop. Across the
LPA family, both Lys39 and Tyr34 are highly conserved, how-
ever, His40 is unique to LPA1 and its protonation may be impor-
tant for high-affinity interactions with the carboxylic acid of
ONO-9780307. Although direct experimental support is needed
to draw definitive conclusions, calculations of binding energy
between wild-type LPA1 with a protonated His40 and ONO-
9780307 compared to a His40Ala in silico mutation showed a
greater than 1 kcal/mol difference in binding affinity supporting
the hypothesis that this position could be partially responsible
Figure 5. Analysis of the Ligand Binding Pocket of LPA1
(A) Detailed binding interactions for ONO-9780307 in the LPA1 pocket. Polar
interactions are represented by dashed yellow lines, and calculated positions
of polar hydrogens are shown to more accurately represent the hydrogen
bonding network. The indane binding pocket is formed by Gly2746.51 and
Leu2756.52 which are represented by van der Waals spheres. Areas for
improving ligand binding are indicated in red text, and red spheres indicate
positions for additional polar interactions.
(B) Binding pocket interactions for additional co-crystal structures of ONO-
9910539 and ONO-3080573. ONO-9910539 has improved interactions due to
the introduction of an acetyl group in the para position of the phenyl ring, which
interacts with Trp2105.43. ONO-3080573 reduces the torsional strain induced
by the indane position in ONO-9780307 through the replacement of a meth-
ylene linker with an ether linkage. In addition replacement of the pyrrole ring
with a para substituted phenyl ring alters the interactions of the acid group
away from the phosphate binding pocket toward Lys2947.36. See also Fig-
ure S2, Tables S1 and S2.for the observed selectivity of this class of antagonists for LPA1
over LPA2 and LPA3 (Table S2, Figure S3, Figure S4 and Supple-
mental Experimental Procedures) (Beard et al., 2013). The polar
binding pocket continues on TMIII, where Arg1243.28 and
Gln1253.29 form ionic and polar interactions with the carboxylic
acid and chiral hydroxyl group of ONO-9780307, respectively.
From TMVII, Glu2937.35 stabilizes the position of Lys39 but
does not directly interact with the ligand (Figure 5A). The bindingpocket surface formed by TMIII and TMV presents a significantly
enhanced polar environment when compared to S1P1, consist-
ing of an Asp1293.33 on TMIII and Trp2105.43 on TMV, which pre-
sents its indole nitrogen for hydrogen bonding interactions with
the antagonist ligands (Figure 5A). Ligand design strategies for
engaging this polarity while reducing lipophilicity were imple-
mented with ONO-9910539, which features an acetyl group in
the para position of the phenyl ring, placing a hydrogen bond
acceptor for interaction with the indole nitrogen of Trp2105.43
(Figure 5B). The torsionally strained bioactive conformation of
ONO-9780307 helps to fill the large spherical binding pocket,
placing the indane ring adjacent to Gly2746.51 on TMVI (Figure 1B
and 5A). Ligand design strategies were implemented for ONO-
3080573, which alleviates this torsional strain by replacing the
methylene linker with an ether moiety (Figure 5B). This replace-
ment was coupled with replacement of the metabolically labile
pyrrole ring found in ONO-9780307 and ONO-9910439 with a
phenyl ring, which differentially positions the carboxylic acid,
breaking interactions with Arg1243.28, His40, and Tyr34 but gain-
ing an interaction with Lys2947.36.
Intersecting Endocannabinoid Pharmacology
The additional polarity provided by Asp1293.33 and Trp2105.43 in
the hydrophobic binding pocket may have implications for spec-
ifying the preference of LPA receptors for long unsaturated acyl
chains, serve as a trigger for agonist induced conformational
changes, and is interesting in the context of GPCR phylogenetic
evolution. The presence of a tryptophan in this position only
occurs in 1% of all class A receptors and is unique to the
lysophospholipid and cannabinoid receptors (Van Durme
et al., 2006). The most abundant endogenous agonist for the
cannabinoid receptor CB1 is 2-arachidonyl glycerol (2-AG; 1,3-
dihydroxy-2-propanyl (5Z,8Z,11Z,14Z)-5,8,11,14-eicosatetrae-
noate) (Stella et al., 1997; Sugiura et al., 1997). Despite binding
at a much lower affinity than the other identified endocannabi-
noid, anandamide, its higher relative abundance makes 2-AG a
major signaling molecule for cannabinoid receptors (Stella
et al., 1997). Interestingly, 2-AG is phosphorylated and con-
verted to 2-arachidonyl phosphatidic acid (2-ALPA) through
the action of monoacylglycerol (MAG) kinase/acyl glycerol ki-
nase (AGK) (Kanoh et al., 1986), producing a potential signaling
molecule accommodated by the spherical LPA1 binding pocket,
although the relative abundance of 2-ALPA has not been inves-
tigated. Furthermore, an alternative biosynthetic pathway has
been reported for the production of anandamide that progresses
through a lysophospholipid analog (pAEA), adding support for
the idea of metabolic cross-talk between LPA and cannabinoid
receptor systems (Figure 6A) (Liu et al., 2006).
The ability of lysophosphatidic acid derivatives of cannabinoid
ligands to bind and activate LPA1 was tested both with 2-ALPA
and pAEA using molecular modeling (Figures 6B and C) and in
receptor signaling assays previously used to define LPA1 as an
LPA receptor (Figure 6D). A model for lipid agonist binding
generated through molecular modeling was used to dock the
endogenous ligands into the LPA1 binding pocket. The slight
expansion of the binding pocket through rotameric shifts of
Trp2105.43 and Trp2716.48, and the exposure of the p clouds of
their respective indole rings enabled favorable interactions withCell 161, 1633–1643, June 18, 2015 ª2015 Elsevier Inc. 1637
Figure 6. Pharmacologically Pleitropic Signaling Lipids Overlap through Common Acyl Chain Binding Pockets in the LPA and Cannabinoid
Receptors and Enzymatic Interconversion of Polar Head Group
(A) The LPA, S1P, and cannabinoid receptors are grouped in the same clade based on a sequence alignment of the transmembrane region. LPA and cannabinoid
receptors are proposed to overlap in ligand specificity when binding polyunsaturated acyl chains delimited by different head group requirements. The
biosynthetic map details the conversion of standard phospholipids to both LPA and CB receptor agonists through common pathways. Both known agonists for
the cannabinoid system (2-AG and AEA) are one enzymatic step away from LPA ligands via phosphorylation of the head group (2-ALPA and pAEA).
(B) Molecular modeling of the endogenous agonist lysophosphatidic acid with an 18 carbon acyl chain (LPA). In the presence of agonist, both Trp2716.48 and
Trp2105.43 are predicted to change rotameric states to increase the volume of the binding pocket and direct the respective aromatic p clouds toward the bound
ligand. The predicted agonist binding pocket is capable of docking 2-ALPA and pAEA, which are generated through enzymatic action from endogenous
cannabinoids.
(legend continued on next page)
1638 Cell 161, 1633–1643, June 18, 2015 ª2015 Elsevier Inc.
the double bonds of the phosphorylated cannabinoid ligands
(Figure 6B). The ability of both 2-ALPA and pAEA to bind in the
modeled agonist pocket without significant ligand strain, sup-
ports the notion that the hydrophobic binding pockets of LPA1
andCB1 can indeed bind the same, poly-unsaturated acyl chains
with metabolically interconvertible head groups.
The molecular modeling provided sufficient rationale for
testing both 2-ALPA and pAEA in LPA1 signaling assays.
Remarkably, all phosphorylated ligands produced robust
signaling as judged by calcium response and cAMP inhibition
in stable cell lines heterologously expressing LPA1 (Fukushima
et al., 1998). Further, a neurite retraction assay, which measures
cell morphology changes mediated by LPA1, showed robust
activation by pAEA (Figure 6D). Neurite retraction involves acti-
vation of the small GTPase Rho that can also activate F-actin
stress fibers in adherent cells, and this classic response was
also activated by pAEA. Together these results highlight the
selectivity of the phosphate headgroup on LPA1 in addition to
the promiscuity of the binding site for acyl chain geometry and
degree of saturation, wherein chemically distinct ligands that
are capable of accessing this space can produce common re-
sponses of receptor activation and down-stream signaling.
DISCUSSION
The growing family of GPCRs mediating membrane-derived
lysophospholipid signals (Kihara et al., 2014) is remarkable for
its ability to respond to diverse changes in the cellular milieu
through multiple signaling mechanisms, and to discriminate
structurally similar molecules. The ability of antagonist structures
to inform receptor agonist binding is atypical, yet may reflect the
evolutionary selection of binding pockets for lipid ligands that are
produced from precursor reservoirs within which the receptors
are embedded, whichmay further contribute to constitutive or in-
verse agonist activities (Bond and Ijzerman, 2006). A somewhat
surprising result was the structural preference of LPA1 for ligand
access from the extracellular milieu, rather than via the mem-
brane as was reported for S1P1. Nevertheless, this structural
prediction is supported by the biological existence and routine
experimental use of albumin bound LPA (Postma et al., 1996)
to activate LPA1 (Fukushima et al., 1998), and is further consis-
tent with the proposed delivery of LPA by its major extracellular
biosynthetic enzyme, autotaxin, via a hydrophobic channel iden-
tified in its crystal structure (Nishimasu et al., 2011). The structure
of LPA1 identified binding interactions between antagonist and
His40, having a calculated pKa of 6.8 and 4.5 in the presence
and absence of ligand, respectively. Although speculative,
computational analysis indicates that full protonation of His40 in-(C) Conformational root mean square fluctuation of LPA over the course of a 100
throughout the calculation indicating a reasonable starting point for modeling ag
(D) Analysis of intracellular signaling and cellular functions in B103 cells heterolo
normalized values (±SEM) to maximum responses induced by 3 mM 1-oleoyl-LP
assay. For the Ca2+ mobilization assay EC50 values for LPA 18:1 sn1 (n = 3), 1-ALP
98 ± 143 nM, and 2,120 ± 3,885 nM, respectively. For the cAMP assay EC50 values
0.302 ± 0.54 nM, and 1.50 ± 2.04 nM, respectively. Neurite retraction was quan
duced by Rho GTPase activation like neurite retraction, were also produced by pA
50 mm). The F-actin stress fiber formation was observed after 15 min treatment wcreases ligand binding affinity by more than 1 kcal/mol (Beard
et al., 2013). If substantiated through direct experimental obser-
vation, this could further support the hypothesis that the
neoplastic activity of LPA1 is enhanced (Hama et al., 2004; Haus-
mann et al., 2011; Mills andMoolenaar, 2003; Perrakis andMoo-
lenaar, 2014) in the acidic environment associated with hypoxic
tumors (Herr et al., 2011; Justus et al., 2013; Kim et al., 2006;
Tannock and Rotin, 1989;Wojtkowiak et al., 2011). Structural an-
alyses predicts a functional complementarity and/or redundancy
between CB1 and LPA1 depending on the balance of phosphor-
ylation states for AEA and 2-AG in particular, since it is a favored
substrate of MAG kinase, at least in the brain (Kanoh et al., 1986).
The interplay of these receptor-ligand systemsmay contribute to
phenotypic variability seen among LPA1 knockout strains and
variable null mutant survival within susceptible strains that are
attributable to brain phenotypes (Contos et al., 2000; Matas-
Rico et al., 2008), since brain expression of both receptors, along
with ligand metabolism, is widespread and can overlap as
occurs in oligodendrocytes (Benito et al., 2007; Weiner et al.,
1998). Complementary access to LPA1 through phosphorylated
CB1 ligands—and vice versa—represent examples of a single
molecular species that could serve as both a primary receptor
modulator and simultaneous prodrug for a different receptor,
as represented by the endocannabinoids acting at their
receptors, with phosphorylation producing selective LPA
receptor ligands. Currently, compounds developed to target
LPA receptors have entered Phase II clinical trials for pulmonary
fibrosis and systemic sclerosis. Compounds exhibiting antago-
nist and/or agonist activity for both the CB1 and LPA1 receptors
have yet to be tested but may be superior for certain indications.EXPERIMENTAL PROCEDURES
Ligand Selection Optimization and Stability Analysis
Compounds based on a 3-pyrrolylpropionic acid core were selected from a
library of previously developed LPA1 antagonists based on superior receptor
stability induction properties (Tanaka et al., 2011). From this initial screen,
ONO-9780307 was selected for structural determination. Analysis of the bind-
ing pocket revealed three regions for improved interactions. ONO-9910539
was designed to improve polar interactions with Trp2105.43 through the intro-
duction of an acetyl moiety on the phenyl ring, and ONO-3080573 was de-
signed to reduce torsional strain associated with the bioactive conformation
of the scaffold through the introduction of an ether linkage to the indane ring
system (Figure 5B, see also Supplemental Experimental Procedures, Figures
S3B and S5 and Table S1).
To measure the effect of compounds on the stability of the receptor, each
compound was tested using a fluorescence based SEC stability assay. Briefly,
after heating the GFP-tagged protein in the presence of ligand, an SEC profile
of each data point was analyzed for fraction of folded protein, which was
plotted as a function of temperature or time to determine approximate meltingns molecular dynamics simulation. The orientation of the ligand is consistent
onist interactions.
gously expressing full-length wild-type LPA1. The data are presented as mean
A (n = 3) for Ca2+ mobilization assay, and by 10 mM forskolin (n = 3) for cAMP
A (n = 3), 2-ALPA (n = 2), and pAEA (n = 2) are 146 ± 74 nM, 1,125 ± 1,484 nM,
for LPA 18:1 sn1 (n = 2), 2-ALPA (n = 2), and pAEA (n = 2) are 0.345 ± 0.202 nM,
tified under microscopic observation. Filamentous (F)-actin stress fibers, pro-
EA stimulation. The representative cell morphologies were shown (scale bars,
ith LPA and pAEA (scale bars, 10 mm).
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Table 1. Crystallographic Data Collection and Refinement
Statistics
Data Collection and Refinement Statistics
Ligand ONO-
9780307
ONO-
9910539
ONO-
3080573
Resolution Cutoff (A˚) 3 2.9 2.9
Number of Crystals 86 53 39
Data Collection Statistics
Space Group P212121 P212121 P212121
Cell Dimensions
a,b,c (A˚)
34.3, 112.2,
154.6
34.6, 112.4,
155.7
34.4, 111.9,
154.0
Number of Reflections
Measured
42,304 27,843 69,138
Number of Unique
Reflections
10,599 10,883 12,701
Resolution (A˚) 45 - 3.0 47 - 2.9 47 - 2.9
(3.16 - 3.0) (3.1 - 2.9) (3.1 - 2.9)
Rmerge 0.19 (0.46) 0.14 (0.49) 0.13 (0.59)
Mean I/s(I) 4.7 (1.4) 4.0 (1.0) 7.2 (1.3)
Completeness 85 (75) 78 (62) 92 (80)
Redundancy 4.0 (2.1) 2.6 (1.7) 5.4 (2.3)
CC1/2 0.99(0.27) 0.99(0.38) 1.0(0.56)
Refinement Statistics
Resolution (A˚) 30 - 3.0 30 - 2.9 30 - 2.9
Number of Reflections
(test set)
10,576 (531) 11,627 (584) 12,660 (625)
Rwork / Rfree (%) 25.4 / 28.1 26.5 / 27.9 27.4 / 29.1
Number of
Atoms
Protein 2,991 2,977 3,014
Ligand 38 41 38
Lipid and other 18 21 21
Average B Factor (A˚2)
Protein 73.2 95.1 87.8
bRIL 95.5 114.8 121.7
Ligand 48.6 70.9 63.7
Lipid and other 62.3 82.2 64.1
RMSD
Bond Lengths (A˚) 0.01 0.009 0.009
Bond Angles (o) 1.08 0.92 0.87
Ramachandran Plot Statistics (%)
Favored Regions 96.3 96.8 97.3
Allowed Regions 3.7 3.2 2.7
Disallowed Regions 0 0 0
Data for high resolution shells is shown in parenthesis where applicable.temperature or half-life, respectively (see also Supplemental Experimental
Procedures and Figure S1).
Crystallization and Diffraction Analysis of LPA1-bRIL and
dsLPA1-mbRIL
Synthetic cDNA encoding the full-length LPA1 receptor was generated with a
stabilized apocytochrome c (bRIL) protein inserted within the third intracel-1640 Cell 161, 1633–1643, June 18, 2015 ª2015 Elsevier Inc.lular loop at positions V232 and R248. Baculovirus directed expression in
Spodoptera frugiperda (Sf9) insect cells was driven by the ie1GP64 promoter
with a cleavable HA signal sequence on the N terminus of the receptor and a
cleavable purification tag consisting of a 103 poly histidine tag upstream of a
FLAG epitope tag. The resulting construct (LPA1-bRIL) was expressed in
Spodoptera frugiperda (Sf9) insect cells using the Bac-to-Bac baculovirus
expression system (Invitrogen) at a yield of 1 mg/l and purified using
IMAC chromatography (see also Supplemental Experimental Procedures).
Protein samples of LPA1-bRIL and dsLPA1-mbRIL were reconstituted into
lipidic cubic phase (LCP) and crystallization set-ups were performed at
room temperature (20C). Data-collection quality crystals were obtained
over a period of 30 days from precipitant condition containing 0.1 M sodium
citrate (pH 5.5), 34% (38% [v/v] PEG400 and 200 mM ammonium acetate;
Figure 2D). Crystals were harvested directly from LCP matrix and flash frozen
in liquid nitrogen for diffraction analysis. X-ray diffraction data were collected
on the 23ID-D/B beamline (GM/CA-CAT) at the Advanced Photon Source
(Argonne, IL) using a 10 mm diameter minibeam with a MarMosaic 300
CCD detector. A rastering and data-collection strategy was followed as pre-
viously described (Cherezov et al., 2009; Hanson et al., 2012). Unattenuated
exposures of 5–10 s per degree were required to observe diffraction to 3 A˚
resolution. Due to the limited amount of data collected per crystal, a protocol
similar to that developed for S1P1 diffraction analysis was utilized to
assemble the data. After data integration and scaling the structures were
solved using molecular replacement followed by multiple cycles of refine-
ment and rebuilding in order to generate the final model (see Supplemental
Experimental Procedures). Statistics are presented in the crystallographic
summary table (Table 1).
Stability Engineering Using Disulfide Bond Addition
Candidates for disulfide bond engineering were generated computationally
using algorithms implemented in BioLuminate (Schro¨dinger, 2012) and similar
to previously described procedures (see also Supplemental Experimental Pro-
cedures) (Salam et al., 2014). Five potential candidates were identified on the
extracellular half of the receptor consisting of two cysteine mutations per site
to facilitate the formation of an additional disulfide bond. After generation of the
mutant constructs and testing for expression, the double mutant D204C and
V282C was selected for crystallization studies. This candidate was selected
due to the enhanced expression profile as compared to the other four con-
structs, which showed little to no expression, as well as an enhanced thermal
stability profile as characterized by the SEC thermal stability assay using highly
purified receptor without a GFP tag (see also Supplemental Experimental
Procedures).
Molecular Modeling and Dynamics Studies
Crystal structures of the S1P1 (PDB ID: 3V2Y) and LPA1 were prepared using
the Schro¨dinger Protein Preparation Wizard (Sastry et al., 2013) and
embedded into a pre-equilibrated POPC (1-palmytoil-2-oleoyl-sn-glycero-
3-phosphatidylcholine) lipid bilayer and solvated with water using the Des-
mond System Builder. Chloride ions were added to neutralize the system
and the ionic strength was set to 0.15 M. The OPLS 2.1 force field (Schro¨-
dinger, 2014d) (Shivakumar et al., 2012) was utilized for all calculations
and systems were relaxed using the default membrane relaxation protocol
as implemented within the Schro¨dinger package. Molecular Dynamics simu-
lations were performed in the NPT ensemble at 300K and 1 atm pressure
using Desmond (D.E. Shaw Research, 2014; Schro¨dinger, 2014c). The two
receptors were analyzed both with and without ligands. Van der Waals and
short range electrostatic interactions were cut off at 9 A˚ and smooth particle
mesh Ewald (PME) (Essmann et al., 1995) method was employed for calcu-
lation of long range electrostatic interactions. The reversible reference sys-
tem propagation algorithm (RESPA) multiple time step approach was used
with a time step of 2 ps and long-ranged electrostatic interactions were
computed every 6 ps (Tuckerman et al., 1992). The temperature and pres-
sure were controlled using a Nose-Hoover chain thermostat (Martyna
et al., 1992) and Martyna-Tobias-Klein (Martyna et al., 1994) barostat,
respectively. Three independent simulations of 100 ns each were performed
for each system on a Nvidia GTX GPU card with coordinates saved every
1.2 ps for subsequent analysis. Molecular dynamics used for docking and
modeling studies utilized similar system parameters but with a 1.2 ns simu-
lation. Coordinates were saved every 1.2 ps and clustered by root mean
square deviation of the residues within a 4 A˚ radius of the ligand. Represen-
tative structures of each cluster were tested for ability to dock endogenous
ligands with minimal torsional strain.
Change in binding affinity toward the ligand ONO-9780307 caused by either
deprotonation of the residue His40 or its mutation to alanine was calculated
using the Residue Scanning functionality in BioLuminate (Schro¨dinger,
2014a) which incorporates the Prime MM-GBSA approach (Beard et al.,
2013). A cutoff of 1 kcal/mol was used as a threshold for defining potential
effect from perturbation.
Quantum mechanical calculations for determining the energy penalty asso-
ciated with the indane position observed in the crystal structures were carried
out after geometry optimizations using Jaguar 8.6 (Schro¨dinger, 2014b) at the
B3LYP/6-31G** level of theory with and without torsional constraints on the in-
dane ring region of the compound.
Functional Analysis Studies
HA-tagged full-length human receptor (LPA1) and disulfide stabilized full-
length human receptor (dsLPA1), DNAs were constructed and cloned into
pCXN2.1 (Niwa et al., 1991). Rat neuroblastoma B103 cells, maintained in
complete media were transfected with each plasmid using GeneJET Plus
(Thermo Scientific) (Fukushima et al., 1998). After 24 hr incubation, media
was replaced with complete media containing 1 mg/ml G418 (Life Technolo-
gies) and the cells were cultured for an additional 2 weeks. Cells labeled
with anti-HA antibody (Roche) followed by PE-conjugated anti rat IgG
(eBioscience) as primary and secondary antibodies, respectively, were sorted
by FACS Aria II (BD Biosciences) using a PE-highly-positive gate, collected,
and cultured in complete media containing Penicillin-Streptomycin (Life Tech-
nologies) to create stable lines.
For Ca2+ measurement, the stable cell lines were starved with FreeStyle 293
Expression Medium (Life Technologies) for at least 1 hr before loading dye
according to the manufacture’s instruction with minor modifications (FLIPR
Calcium 4 Assay Kit; Molecular Device). Intracellular Ca2+ mobilization was
monitored in response to increasing ligand concentration using a scanning
fluorimeter (FLEXstation 3; Molecular Devices) at an excitation wavelength of
485 nm and an emission wavelength of 525 nm.
For cAMP assay, stable cell lines were starved with FreeStyle 293 Expres-
sion Medium (Life Technologies) overnight. The cells were incubated with
ligands for 30 min at room temperature in Hank’s Balanced Salt Solution con-
taining 10 mM forskolin and 0.5 mM 3-isobutyl-1-methylxanthine. Intracellular
cAMP levels were determined using a cAMP-Screen System (Applied Bio-
systems) according to the manufacturer’s instructions.
For neurite retraction and stress fiber formation assay, stable cell lines
were starved with FreeStyle 293 Expression Medium (Life Technologies)
overnight. The cells were incubated with ligands for 15 min at 37C, washed
and then fixed with 2% paraformaldehyde. Cells with round morphology
lacking neurite extensions were counted and represented as a percentage
of the observed cells. The f-actin stress fiber formation was studied using
rhodamine phalloidin staining. Fixed cells were washed with 0.3% Triton
X-100 in PBS, and stained with 1 mg/ml rhodamine-phalloidin for 30 min at
room temperature. After washing, the cells were mounted using Vectorshield
(Vector Laboratory). Images were captured using a Nikon C2 laser-scanning
confocal microscope.
Standard lipids were obtained from commercial sources: 1-oleoyl-LPA and
1-arachidonoyl-LPA (Avanti Polar Lipids), AEA, 2-AG and pAEA (Cayman
Chemical). Enzymatic synthesis was employed for 2-arachidonoyl-LPA that
was enzymatically synthesized from 1,2-diarachidonoyl-sn-glycero-3-phos-
phate (diarachidonoyl-PA) (Avanti Polar lipids) using Rhizopus arrhizus lipase
(Sigma) (see also Supplemental Experimental Procedures).ACCESSION NUMBERS
Coordinates and structures factors have been deposited in the Protein Data
Bank for LPA1-ONO9780307, LPA1-ONO9910539 and LPA1-ONO3080573
(PDB: 4Z34, 4Z35, 4Z36).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2015.06.002.
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